Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)

Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (LK-423)

The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: TATJANA MATEOVIC, DORIS TIBAUT, SHIZUKO MURAOKA, GRETA COF, ANTON STALC, JANEZ KERK, MARIJA BOGATAJ, FUMIO YONEDA, ROK DREU, ANTON LAVRIC, UROS URLEB, ALES MRHAR, MANICA CERNE
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.